Therefore, to avoid inaccuracy of HOMA-IR and HOMA-B caused by the prescribed insulin and other treatments in T2DM patients, fasting plasma C-peptide was used instead of fasting insulin [17]. This evidence concerns the gene INS and type 2 diabetes mellitus.